The multiple‐kinase inhibitor lenvatinib inhibits the proliferation of acute myeloid leukemia cells

Abstract

Background: Current chemotherapy for acute myeloid leukemia (AML) mainly involves cytotoxic agents such as doxorubicin (DNR), mitoxantrone (Mito) or 2-aminopurine-6-thiol (6-TG). However, because these agents are relatively ineffective, discovering other more effective drugs for AML treatment would be valuable. Methods:The in vitro antitumor effect of lenvatinib on AML cells was examined using the colorimetric MTT assay for assessing cell metabolic activity. AML cells mixed with Poloxamer 407 were injected into nude mice to form subcutaneous tumors. Tumorbearing mice received lenvatinib by oral administration. The antitumor effect of lenvatinib was established by measuring tumor volumes and weights. Results: Lenvatinib inhibited the growth of AML cells in a dose-dependent manner.We used AML cells to establish subcutaneous tumor tissues by mixing the cell suspension with Poloxamer 407. Poloxamer 407 alone did not influence the subcutaneous growth of AML cells. Treatment of lenvatinib inhibited in vivo tumor growth of AML cells. Conclusion: The multiple-kinase inhibitor lenvatinib inhibits the in vitro proliferation of AML cells, and restricts the in vivo growth of AML tumors. K E Y W O R D S acute myeloid leukemia, lenvatinib, molecular targeting agents S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article: Feng F, Li X, Li R, Li B. The multiplekinase inhibitor lenvatinib inhibits the proliferation of acute myeloid leukemia cells. Animal Model Exp Med. 2019;2:178-184. https ://doi.

miR-27-3p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to the Antitumor Agent Olaparib by Targeting PSEN-1, the Catalytic Subunit of Γ-Secretase

“…( 39 ) and Feng et al. ( 40 – 42 ). After olaparib treatment, the samples were harvested from the mice, and the expression of Notch pathway-related factors in tissues was examined by qPCR.…”

“…The cells were injected into nude mice subcutaneously. Then, the mice received olaparib via oral administration in accordance with the methods described by Sun HW et al (39) and Feng et al (40)(41)(42). After olaparib treatment, the samples were harvested from the mice, and the expression of Notch pathway-related factors in tissues was examined by qPCR.…”

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4

“…Female nude mice were purchased from the Si-Bei-Fu Corporation, Beijing China. Following transfection, MHCC97-H cells were prepared as a single-cell suspension and subcutaneously injected into nude mice ( 39 , 40 ). The mice orally received sorafenib once every two days.…”

“…The mice orally received sorafenib once every two days. Tumors from the mice were harvested, and the volumes and weights were measured ( 39 , 40 ).…”

<p>Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents</p>

“…In order to produce the nude mice subcutaneous tumor model, MHCC97-H cells were cultured, prepared and subcutaneously injected into the 4-5 week-old nude mice. 42,56 Four to 5 days after injection, the assigned concentrations of agents were orally administrated into the mice every 2 days. Mice were cultivated in cages and their tumor tissues were collected after 30 days of oral administration (15 times).…”